Cargando…
Nonclinical regulatory immunotoxicity testing of nanomedicinal products: Proposed strategy and possible pitfalls
Various nanomedicinal products (NMPs) have been reported to induce an adverse immune response, which may be related to their tendency to accumulate in or target cells of the immune system. Therefore, before their market authorization, NMPs should be thoroughly evaluated for their immunotoxic potenti...
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley & Sons, Inc.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7507198/ https://www.ncbi.nlm.nih.gov/pubmed/32266791 http://dx.doi.org/10.1002/wnan.1633 |